TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04423887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Plan
Description: 2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Plan
Description: 2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension
Study: NCT03958656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells
Description: 0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
Study: NCT00622700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet Oral administration
Study: NCT03845881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
Study: NCT03400579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC® device
Description: The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
Study: NCT02769247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: either normal saline or empty oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: either normal saline or empty oral capsule
Study: NCT04811105

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: steam ablation
Description: 32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: steam ablation
Description: 32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
Study: NCT02133287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVI® Arsenic trioxide drug eluting stent delivery system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Firebird2® sirolimus eluting stent system
Study: NCT02349581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS block
Description: Ultrasound guided delivery of local anesthetic between the pectoral muscles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study: NCT03165279

Intervention type: PROCEDURE
Intervention: Zenith Alpha Abdominal stentgraft
Study: NCT04665284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
Study: NCT01433601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Treatment Support (ETS)
Description: An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup.
Study: NCT02737644

Intervention type: OTHER
Intervention: observation
Description: This is an observational study
Study: NCT03226392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAW039
Description: QAW039 once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT01604122

Intervention type: OTHER
Intervention: No drug
Description: No drug.
Study: NCT02338531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast cancer surgery
Study: NCT02573727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nor adrenaline + albumin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin + albumin
Study: NCT03992157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG telemetry
Description: ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
Study: NCT01406431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin, Valsartan
Description: Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
Study: NCT03984149

Intervention type: OTHER
Intervention: Observational study
Description: Observational study: There is no intervention.
Study: NCT01304368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotherapy
Description: Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
Study: NCT01406431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livalo® fixed combination drug
Description: Livalo® fixed combination drug(1 tablet)
Study: NCT04101981

Intervention type: PROCEDURE
Intervention: oocytes retrieval
Description: The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.

Intervention type: PROCEDURE
Intervention: oocytes retrieval
Description: The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
Study: NCT02834533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat
Description: Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat
Description: Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
Study: NCT03241355

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: prebiotic inulin-type fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maltodextrin
Study: NCT03562104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: videofluoroscopy
Description: Swallowing description in Minimally consciousness Patient
Study: NCT05646160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)
Description: IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
Study: NCT03281356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Participants will receive a total of 8 text messages during a 4 week period.
Study: NCT03018340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
Study: NCT01550315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsitile Arterial Tonometry (PAT) Protocol
Description: * A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulsitile Arterial Tonometry (PAT) Protocol
Description: * A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped.
Study: NCT03562104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wessex Head Injury Matrix scale
Description: Wessex Head Injury Matrix scale in Minimally consciousness Patient
Study: NCT01404845

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrof Total
Description: Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrof Total
Description: Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food supplement without Lutein and Zeaxanthin
Description: food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food supplement without Lutein and Zeaxanthin
Description: food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
Study: NCT03643094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Golden Black Seed
Description: 1 capsule per day for 8 weeks.
Study: NCT01018368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
Study: NCT01018368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
Study: NCT02609048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Capsule (2 taken once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Seladelpar / MBX-8025 50 mg
Description: MBX-8025 50 mg capsule (1 taken once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Seladelpar / MBX-8025 200 mg
Description: MBX-8025 100 mg capsules (2 taken once daily)
Study: NCT04524559

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional physical therapy training
Description: The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy training
Description: The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral motor training.
Description: Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization
Study: NCT00167102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alefacept
Description: Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
Study: NCT00609791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: 100 mg/m2 3 weeks on 1 week off

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiologic testing
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Study: NCT00159913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral; 20mg, 40mg and 80 mg; 3 times a day(TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral; 10mg, 20mg and 40mg; 3 times a day(TID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral; 3 times a day(TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral; 10 mg; 3 times a day(TID)
Study: NCT04453813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus concurrent chemo-radiotherapy
Description: 1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemo-radiotherapy
Description: 1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy
Study: NCT00685646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen therapy
Description: Up to 24 courses of therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiandrogen therapy
Description: Up to 24 courses of therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Up to 24 courses of therapy
Study: NCT01338610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESBA105 ophthalmic solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ESBA105 vehicle
Description: Inactive ingredients used as Run-In and placebo comparator
Study: NCT03679299

Intervention type: OTHER
Intervention: Observational - No intervention
Description: See outcomes

Intervention type: OTHER
Intervention: Observational - No intervention
Description: See outcomes